These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 26661693)

  • 1. Prediction of 10-year vascular risk in patients with diabetes: the AD-ON risk score.
    Woodward M; Hirakawa Y; Kengne AP; Matthews DR; Zoungas S; Patel A; Poulter N; Grobbee R; Cooper M; Jardine M; Chalmers J;
    Diabetes Obes Metab; 2016 Mar; 18(3):289-94. PubMed ID: 26661693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes.
    Mohammedi K; Woodward M; Marre M; Colagiuri S; Cooper M; Harrap S; Mancia G; Poulter N; Williams B; Zoungas S; Chalmers J
    Cardiovasc Diabetol; 2017 Jul; 16(1):95. PubMed ID: 28750645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erectile dysfunction and later cardiovascular disease in men with type 2 diabetes: prospective cohort study based on the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation) trial.
    Batty GD; Li Q; Czernichow S; Neal B; Zoungas S; Huxley R; Patel A; de Galan BE; Woodward M; Hamet P; Harrap SB; Poulter N; Chalmers J;
    J Am Coll Cardiol; 2010 Nov; 56(23):1908-13. PubMed ID: 21109113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial.
    de Galan BE; Zoungas S; Chalmers J; Anderson C; Dufouil C; Pillai A; Cooper M; Grobbee DE; Hackett M; Hamet P; Heller SR; Lisheng L; MacMahon S; Mancia G; Neal B; Pan CY; Patel A; Poulter N; Travert F; Woodward M;
    Diabetologia; 2009 Nov; 52(11):2328-2336. PubMed ID: 19688336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New insights from ADVANCE.
    Chalmers J; Kengne AP; Joshi R; Perkovic V; Patel A
    J Hypertens Suppl; 2007 Jun; 25(1):S23-30. PubMed ID: 17579315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial.
    Zoungas S; de Galan BE; Ninomiya T; Grobbee D; Hamet P; Heller S; MacMahon S; Marre M; Neal B; Patel A; Woodward M; Chalmers J; ; Cass A; Glasziou P; Harrap S; Lisheng L; Mancia G; Pillai A; Poulter N; Perkovic V; Travert F
    Diabetes Care; 2009 Nov; 32(11):2068-74. PubMed ID: 19651921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study rationale and design of ADVANCE: action in diabetes and vascular disease--preterax and diamicron MR controlled evaluation.
    ADVANCE Management Committee
    Diabetologia; 2001 Sep; 44(9):1118-20. PubMed ID: 11596665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial.
    Hirakawa Y; Arima H; Zoungas S; Ninomiya T; Cooper M; Hamet P; Mancia G; Poulter N; Harrap S; Woodward M; Chalmers J
    Diabetes Care; 2014 Aug; 37(8):2359-65. PubMed ID: 24812434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting the effects of blood pressure-lowering treatment on major cardiovascular events for individual patients with type 2 diabetes mellitus: results from Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation.
    van der Leeuw J; Visseren FL; Woodward M; Zoungas S; Kengne AP; van der Graaf Y; Glasziou P; Hamet P; MacMahon S; Poulter N; Grobbee DE; Chalmers J
    Hypertension; 2015 Jan; 65(1):115-21. PubMed ID: 25312436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Framingham and UK Prospective Diabetes Study (UKPDS) risk equations do not reliably estimate the probability of cardiovascular events in a large ethnically diverse sample of patients with diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation (ADVANCE) Study.
    Kengne AP; Patel A; Colagiuri S; Heller S; Hamet P; Marre M; Pan CY; Zoungas S; Grobbee DE; Neal B; Chalmers J; Woodward M;
    Diabetologia; 2010 May; 53(5):821-31. PubMed ID: 20157695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes.
    Zoungas S; Chalmers J; Neal B; Billot L; Li Q; Hirakawa Y; Arima H; Monaghan H; Joshi R; Colagiuri S; Cooper ME; Glasziou P; Grobbee D; Hamet P; Harrap S; Heller S; Lisheng L; Mancia G; Marre M; Matthews DR; Mogensen CE; Perkovic V; Poulter N; Rodgers A; Williams B; MacMahon S; Patel A; Woodward M;
    N Engl J Med; 2014 Oct; 371(15):1392-406. PubMed ID: 25234206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Haemoglobin glycation index and risk for diabetes-related complications in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial.
    van Steen SC; Woodward M; Chalmers J; Li Q; Marre M; Cooper ME; Hamet P; Mancia G; Colagiuri S; Williams B; Grobbee DE; DeVries JH;
    Diabetologia; 2018 Apr; 61(4):780-789. PubMed ID: 29308539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Intensive Glycemic Control on Clinical Outcomes Among Patients With Type 2 Diabetes With Different Levels of Cardiovascular Risk and Hemoglobin A
    Tian J; Ohkuma T; Cooper M; Harrap S; Mancia G; Poulter N; Wang JG; Zoungas S; Woodward M; Chalmers J
    Diabetes Care; 2020 Jun; 43(6):1293-1299. PubMed ID: 32193249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contemporary model for cardiovascular risk prediction in people with type 2 diabetes.
    Kengne AP; Patel A; Marre M; Travert F; Lievre M; Zoungas S; Chalmers J; Colagiuri S; Grobbee DE; Hamet P; Heller S; Neal B; Woodward M;
    Eur J Cardiovasc Prev Rehabil; 2011 Jun; 18(3):393-8. PubMed ID: 21450612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What matters in ADVANCE and ADVANCE-ON.
    Hamet P
    Diabetes Obes Metab; 2012 Jan; 14 Suppl 1():20-9. PubMed ID: 22118707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical trial of the month. ADVANCE: improved survival and better vascular and renal outcomes with a fixed combination of perindopril and indapamide in patients with type 2 diabetes].
    Scheen AJ; Krzesinski JM
    Rev Med Liege; 2007 Oct; 62(10):639-43. PubMed ID: 18069576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Risks of Cardiovascular Disease and Mortality Following Weight Change in Adults with Diabetes: Results from ADVANCE.
    Lee AK; Woodward M; Wang D; Ohkuma T; Warren B; Sharrett AR; Williams B; Marre M; Hamet P; Harrap S; Mcevoy JW; Chalmers J; Selvin E
    J Clin Endocrinol Metab; 2020 Jan; 105(1):152-62. PubMed ID: 31588504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood pressure and glucose control in subjects with diabetes: new analyses from ADVANCE.
    Poulter NR
    J Hypertens Suppl; 2009 May; 27(1):S3-8. PubMed ID: 19483505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal protection: What have we learnt from ADVANCE about kidney disease in type 2 diabetes?
    Knudsen ST; Cooper ME
    Diabetes Obes Metab; 2020 Apr; 22 Suppl 2():12-18. PubMed ID: 31729127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes.
    van der Leeuw J; Visseren FL; Woodward M; van der Graaf Y; Grobbee DE; Harrap S; Heller S; Mancia G; Marre M; Poulter N; Zoungas S; Chalmers J
    Diabetologia; 2016 Dec; 59(12):2603-2612. PubMed ID: 27586250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.